BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34245928)

  • 1. Early Post-Transplantation Serum Ferritin Level Predicts Survival in Recipients of Haploidentical Stem Cell Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis.
    Jullien M; Orvain C; Berceanu A; Couturier MA; Guillaume T; Peterlin P; Garnier A; Bourgeois AL; Klemencie M; Schmidt A; Hunault M; Daguindau E; Roussel X; Delepine P; Guillerm G; Giltat A; François S; Thepot S; Gouill SL; Béné MC; Chevallier P
    Transplant Cell Ther; 2021 Oct; 27(10):861.e1-861.e7. PubMed ID: 34245928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
    Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
    Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
    Montoro J; Boumendil A; Finel H; Bramanti S; Castagna L; Blaise D; Dominietto A; Kulagin A; Yakoub-Agha I; Tbakhi A; Solano C; Giebel S; Gulbas Z; López Corral L; Pérez-Simón JA; Díez Martín JL; Sanz J; Farina L; Koc Y; Socié G; Arat M; Jurado M; Bermudez A; Labussière-Wallet H; Villalba M; Ciceri F; Martinez C; Nagler A; Sureda A; Glass B
    Transplant Cell Ther; 2024 Feb; 30(2):210.e1-210.e14. PubMed ID: 38043802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Infections and Delayed CD4
    Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
    Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B Seropositive Status in Recipients or Donors Is Not Related to Worse Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation.
    Yu C; Sun Y; Xu L; Zhang X; Liu K; Jin J; Huang X; Wang Y
    Transplant Cell Ther; 2021 Aug; 27(8):668.e1-668.e9. PubMed ID: 34052506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide.
    Jullien M; Orvain C; Berceanu A; Couturier MA; Guillaume T; Peterlin P; Garnier A; Le Bourgeois A; Klemencie M; Schmidt A; Hunault M; Daguindau E; Roussel X; Delepine P; Guillerm G; Giltat A; François S; Thepot S; Le Gouill S; Béné MC; Chevallier P
    Cancer Med; 2021 Oct; 10(20):7194-7202. PubMed ID: 34547182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation.
    Wada F; Kanda J; Kamijo K; Nishikubo M; Yoshioka S; Ishikawa T; Ueda Y; Akasaka T; Arai Y; Izumi K; Hirata H; Ikeda T; Yonezawa A; Anzai N; Watanabe M; Imada K; Yago K; Tamura N; Itoh M; Masuo Y; Kunitomi A; Takeoka T; Kitano T; Arima N; Hishizawa M; Asagoe K; Kondo T; Takaori-Kondo A
    Cell Transplant; 2023; 32():9636897231194497. PubMed ID: 37646153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor.
    Blaise D; Fürst S; Crocchiolo R; El-Cheikh J; Granata A; Harbi S; Bouabdallah R; Devillier R; Bramanti S; Lemarie C; Picard C; Chabannon C; Weiller PJ; Faucher C; Mohty B; Vey N; Castagna L
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):119-24. PubMed ID: 26341397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Arcuri LJ; Aguiar MTM; Ribeiro AAF; Pacheco AGF
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2422-2430. PubMed ID: 31386903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.
    Yu X; Liu L; Xie Z; Dong C; Zhao L; Zhang J; Gu J; Zhu HH
    Crit Rev Oncol Hematol; 2019 Jan; 133():120-128. PubMed ID: 30661648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppression-Free Status at 1 Year after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.
    Solh M; Bashey A; Zhang X; Holland HK; Bachier-Rdriguez L; Morris LE; Solomon SR
    Transplant Cell Ther; 2024 Jun; 30(6):607.e1-607.e8. PubMed ID: 38552844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Fanconi Anemia: Improving Outcomes with Improved Supportive Care in India.
    Uppuluri R; Swaminathan VV; Ramanan KM; Meena S; Varla H; Ramakrishnan B; Jayakumar I; Raj R
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2292-2298. PubMed ID: 32835780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor.
    Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1655-1662. PubMed ID: 32504861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide.
    Shimomura Y; Komukai S; Kitamura T; Sobue T; Akahoshi Y; Kanda J; Ohigashi H; Nakamae H; Hiramoto N; Nagafuji K; Tanaka T; Eto T; Ota S; Maruyama Y; Akasaka T; Matsuoka KI; Mori Y; Fukuda T; Atsuta Y; Terakura S
    Bone Marrow Transplant; 2024 Jan; 59(1):66-75. PubMed ID: 37898725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
    Cieri N; Greco R; Crucitti L; Morelli M; Giglio F; Levati G; Assanelli A; Carrabba MG; Bellio L; Milani R; Lorentino F; Stanghellini MT; De Freitas T; Marktel S; Bernardi M; Corti C; Vago L; Bonini C; Ciceri F; Peccatori J
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1506-14. PubMed ID: 26001696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant cyclophosphamide for GVHD prophylaxis in pediatrics with chronic active Epstein-Barr virus infection after haplo-HSCT.
    Luo R; Zhang X; Wang Y; Man Q; Gu W; Tian Z; Wang J
    Orphanet J Rare Dis; 2022 Dec; 17(1):422. PubMed ID: 36461028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation.
    Dybko J; Sobczyk-Kruszelnicka M; Makuch S; Agrawal S; Dudek K; Giebel S; Gil L
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG).
    Tang F; Xu Y; Chen H; Xu L; Zhang X; Wang Y; Liu Q; Wu D; Huang X
    Sci China Life Sci; 2020 Apr; 63(4):571-581. PubMed ID: 31420852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.